Skip to content

Vir Biotechnology, Inc. VIR Convertible Preferred Stock Issued Shares

Convertible Preferred Stock Issued Shares at other companies

Biohaven logo
BiohavenBHVN
0
Moderna logo
ModernaMRNA
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue-$29.0K-101%
Gross profit$1.2M-60.2%
Operating income-$132.3M+5.2%
Net income-$125.7M-3.9%
EPS (diluted)-$0.85+3.4%

Balance sheet

See full
Cash & equivalents$283.0M-23.1%
Total debt$95.6M-0.5%
Total equity$812.8M-22.1%
Total assets$1.0B-21.6%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$390.0K-76.1%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.68B+61.1%

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-720.8%-313pp
Net margin-676%-291pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-47.7%+3.6pp
Debt / equity0.1×0.0×
Current ratio7.1×+0.3×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Vir Biotechnology, Inc.'s convertible preferred stock issued shares?
Vir Biotechnology, Inc. (VIR) reported convertible preferred stock issued shares of 0 in Q1 2026.
What does convertible preferred stock issued shares mean?
Number of convertible preferred shares that have been issued, whether held by investors or in treasury.